• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    RXO, Alnylam Pharmaceuticals And Other Big Stocks Moving Lower In Monday's Pre-Market Session

    6/24/24 7:54:53 AM ET
    $ALNY
    $ALT
    $ARGX
    $CLOV
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ALNY alert in real time by email

    U.S. stock futures were mostly higher this morning, with the Dow futures gaining around 100 points on Monday.

    Shares of RXO, Inc.. (NYSE:RXO) shares rose sharply in today's pre-market trading after the company inked a definitive agreement to acquire Coyote Logistics from United Parcel Service, Inc. (NYSE:UPS) for $1.025 billion in cash.

    As per the terms, the transaction disclosed on Sunday will be financed through a combination of equity and debt, including a $300 million equity investment from MFN Partners and a $250 million equity investment from Orbis Investments, both significant shareholders of RXO.

    RXO shares jumped 13.3% to $22.90 in pre-market trading.

    Here are some big stocks recording losses in today's pre-market trading session.

    • Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) shares gained 38.8% to $230.00 in pre-market trading after announcing topline results from its HELIOS-B Phase 3 study of vutrisiran.
    • Altimmune, Inc. (NASDAQ:ALT) shares gained 10.9% to $7.10 in pre-market trading after the company announced that it presented data from the 48-week Phase 2 MOMENTUM clinical trial of pemvidutide at the American Diabetes Association’s 84th Scientific Sessions.
    • Clover Health Investments, Corp. (NASDAQ:CLOV) gained 9.6% to $1.37 in pre-market trading after gaining over 21% on Friday.
    • argenx SE (NASDAQ:ARGX) shares gained 9.9% to $433.52 in pre-market trading after the company announced the FDA approval of VYVGART Hytrulo for chronic inflammatory demyelinating polyneuropathy.
    • Intellia Therapeutics, Inc. (NASDAQ:NTLA) shares gained 9.5% to $26.51 in pre-market trading.
    • Pharming Group N.V. (NASDAQ:PHAR) shares gained 8.1% to $7.86 in pre-market trading after declining 8% on Friday.
    • Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) shares gained 5.2% to $44.01 in pre-market trading.

    Now Read This: Investor Optimism Improves Despite Stocks Ending Mixed On Friday: S&P 500 Closes Lower With Nvidia Dropping Over 3%, Dow Jones Ends Marginally Higher

    Don't forget to check out our premarket coverage here

    Get the next $ALNY alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALNY
    $ALT
    $ARGX
    $CLOV

    CompanyDatePrice TargetRatingAnalyst
    Altimmune Inc.
    $ALT
    3/18/2026$12.00Buy
    Truist
    Alnylam Pharmaceuticals Inc.
    $ALNY
    3/16/2026$330.00Buy → Hold
    Jefferies
    argenx SE
    $ARGX
    3/10/2026Hold → Buy
    Deutsche Bank
    Intellia Therapeutics Inc.
    $NTLA
    3/2/2026Mkt Perform → Outperform
    William Blair
    United Parcel Service Inc.
    $UPS
    1/28/2026Hold → Buy
    HSBC Securities
    Ionis Pharmaceuticals Inc.
    $IONS
    1/28/2026$95.00Overweight
    Barclays
    Altimmune Inc.
    $ALT
    1/28/2026$20.00Overweight
    Barclays
    Alnylam Pharmaceuticals Inc.
    $ALNY
    1/28/2026$527.00Overweight
    Barclays
    More analyst ratings

    $ALNY
    $ALT
    $ARGX
    $CLOV
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for GIVLAARI issued to ALNYLAM PHARMS INC

    Submission status for ALNYLAM PHARMS INC's drug GIVLAARI (SUPPL-7) with active ingredient GIVOSIRAN SODIUM has changed to 'Approval' on 04/29/2024. Application Category: NDA, Application Number: 212194, Application Classification: Labeling

    4/30/24 1:44:03 PM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for OXLUMO issued to ALNYLAM PHARMS INC

    Submission status for ALNYLAM PHARMS INC's drug OXLUMO (SUPPL-4) with active ingredient LUMASIRAN SODIUM has changed to 'Approval' on 09/19/2023. Application Category: NDA, Application Number: 214103, Application Classification: Labeling

    9/20/23 2:36:38 PM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for AMVUTTRA issued to ALNYLAM PHARMS INC

    Submission status for ALNYLAM PHARMS INC's drug AMVUTTRA (SUPPL-2) with active ingredient VUTRISIRAN has changed to 'Approval' on 02/16/2023. Application Category: NDA, Application Number: 215515, Application Classification: Labeling

    2/17/23 12:30:09 PM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALNY
    $ALT
    $ARGX
    $CLOV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Priest Brady Patrick

    4 - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Issuer)

    4/3/26 4:59:27 PM ET
    $CLOV
    Medical Specialities
    Health Care

    SEC Form 4 filed by Reynoso Jamie L.

    4 - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Issuer)

    4/3/26 4:34:43 PM ET
    $CLOV
    Medical Specialities
    Health Care

    SEC Form 4 filed by Toy Andrew

    4 - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Issuer)

    4/3/26 4:31:15 PM ET
    $CLOV
    Medical Specialities
    Health Care

    $ALNY
    $ALT
    $ARGX
    $CLOV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    CAMBRIDGE, Mass., April 03, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that on April 1, 2026, it awarded inducement grants to 13 new employees under Intellia's 2024 Inducement Plan, as amended, as a material inducement to employment. The inducement grants consisted of time-based restricted stock units ("RSUs") for an aggregate of 67,150 shares of Intellia's common stock, with one-third of such RSUs vesting annually over three years. All equity vesting is subject to each employee's continued service as an employee of, o

    4/3/26 4:05:00 PM ET
    $NTLA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    RXO Schedules First-Quarter 2026 Earnings and Investor Conference Call for May 7, 2026

    RXO (NYSE:RXO) will issue its first-quarter financial results before the opening of the New York Stock Exchange on Thursday, May 7, 2026. The company's results will be made available on www.rxo.com. The company will also hold a conference call at 8 a.m. EDT. Conference Call Access Information Live webcast online at: http://investors.rxo.com Call toll-free from U.S./Canada: +1 800-715-9871 International callers: +1 646-307-1963 Conference ID: 8661113 A replay of the conference call will be available through May 14, 2026, by calling toll-free (from U.S./Canada) +1 800-770-2030; international callers dial +1 609-800-9909. Use the passcode 8661113#. Additionally, the call will be archived

    4/2/26 8:30:00 AM ET
    $RXO
    Transportation Services
    Consumer Discretionary

    Clover Health Announces Departure of Chief Financial Officer and Appointment of Interim Chief Financial Officer; Reiterates Most Recently Issued Financial Guidance for Full Fiscal Year 2026

    WILMINGTON, Del., April 01, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover" or the "Company"), a physician enablement company committed to bringing access to great healthcare to everyone on Medicare, today announced that Peter Kuipers is stepping down as the Chief Financial Officer of the Company, effective March 30, 2026. Mr. Kuipers will remain with the Company in an advisory capacity through April 24, 2026 to support a smooth transition and handoff. Mr. Kuipers and the Company noted that his departure does not reflect any disagreement with the Company on any matter relating to the Company's operations, policies or practices. The Board of Directors has

    4/1/26 8:30:00 AM ET
    $CLOV
    Medical Specialities
    Health Care

    $ALNY
    $ALT
    $ARGX
    $CLOV
    SEC Filings

    View All

    SEC Form 6-K filed by Pharming Group N.V. ADS each representing 10

    6-K - Pharming Group N.V. (0001828316) (Filer)

    4/2/26 6:10:50 AM ET
    $PHAR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 20-F filed by Pharming Group N.V. ADS each representing 10

    20-F - Pharming Group N.V. (0001828316) (Filer)

    4/2/26 6:03:01 AM ET
    $PHAR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Clover Health Investments Corp. filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits

    8-K - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Filer)

    4/1/26 8:32:45 AM ET
    $CLOV
    Medical Specialities
    Health Care

    $ALNY
    $ALT
    $ARGX
    $CLOV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Weaver Gregory L bought $17,700 worth of shares (5,000 units at $3.54), increasing direct ownership by 22% to 28,078 units (SEC Form 4)

    4 - Altimmune, Inc. (0001326190) (Issuer)

    3/9/26 7:05:04 AM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and CEO Durso Jerome Benedict bought $70,790 worth of shares (20,000 units at $3.54), increasing direct ownership by 160% to 32,500 units (SEC Form 4)

    4 - Altimmune, Inc. (0001326190) (Issuer)

    3/9/26 7:00:05 AM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Mfn Partners, Lp bought $6,387,312 worth of shares (532,276 units at $12.00) (SEC Form 4)

    4 - RXO, Inc. (0001929561) (Issuer)

    2/17/26 4:21:23 PM ET
    $RXO
    Transportation Services
    Consumer Discretionary

    $ALNY
    $ALT
    $ARGX
    $CLOV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Truist initiated coverage on Altimmune with a new price target

    Truist initiated coverage of Altimmune with a rating of Buy and set a new price target of $12.00

    3/18/26 4:00:13 PM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alnylam Pharma downgraded by Jefferies with a new price target

    Jefferies downgraded Alnylam Pharma from Buy to Hold and set a new price target of $330.00

    3/16/26 8:35:18 AM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    argenx upgraded by Deutsche Bank

    Deutsche Bank upgraded argenx from Hold to Buy

    3/10/26 3:28:52 PM ET
    $ARGX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALNY
    $ALT
    $ARGX
    $CLOV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Ionis Pharmaceuticals Inc.

    SC 13G/A - IONIS PHARMACEUTICALS INC (0000874015) (Subject)

    11/14/24 8:34:57 PM ET
    $IONS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Ionis Pharmaceuticals Inc.

    SC 13G/A - IONIS PHARMACEUTICALS INC (0000874015) (Subject)

    11/14/24 1:28:29 PM ET
    $IONS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by argenx SE

    SC 13G/A - ARGENX SE (0001697862) (Subject)

    11/14/24 1:22:37 PM ET
    $ARGX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALNY
    $ALT
    $ARGX
    $CLOV
    Leadership Updates

    Live Leadership Updates

    View All

    Clover Health Announces Departure of Chief Financial Officer and Appointment of Interim Chief Financial Officer; Reiterates Most Recently Issued Financial Guidance for Full Fiscal Year 2026

    WILMINGTON, Del., April 01, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover" or the "Company"), a physician enablement company committed to bringing access to great healthcare to everyone on Medicare, today announced that Peter Kuipers is stepping down as the Chief Financial Officer of the Company, effective March 30, 2026. Mr. Kuipers will remain with the Company in an advisory capacity through April 24, 2026 to support a smooth transition and handoff. Mr. Kuipers and the Company noted that his departure does not reflect any disagreement with the Company on any matter relating to the Company's operations, policies or practices. The Board of Directors has

    4/1/26 8:30:00 AM ET
    $CLOV
    Medical Specialities
    Health Care

    argenx announces Annual General Meeting of Shareholders on May 6, 2026

    March 20, 2026 Amsterdam, the Netherlands – argenx SE ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that the Annual General Meeting of shareholders will be held at 13:00 CET on Wednesday, May 6, 2026 at the Hilton Amsterdam Schiphol at Schiphol Boulevard 701, 1118 BN Schiphol, the Netherlands.The shareholders and all other persons with meeting rights are invited to attend the Annual General Meeting of shareholders. The formal notice of convocation (including information on attending the meeting in person or by proxy, requirements for notification and registration for the meeting a

    3/20/26 4:01:00 PM ET
    $ARGX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Ionis announces changes to Board of Directors

    – Lynne Parshall and Joseph Wender to retire at end of term in June 2026 and Peter Reikes to join Ionis Board – Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) today announced upcoming transitions on its Board of Directors. B. Lynne Parshall, Esq., and Joseph Wender will be retiring at the end of their term and Peter N. Reikes will be rejoining as a director. The changes will be effective June 4, 2026. Ms. Parshall has served as a director since September 2000. Previously, she served as Ionis' chief operating officer from December 2007 through December 2017 and as chief financial officer from June 1994 through December 2012. Ms. Parshall joined Ionis in 1991 and served in various executive ro

    3/9/26 7:00:00 AM ET
    $IONS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALNY
    $ALT
    $ARGX
    $CLOV
    Financials

    Live finance-specific insights

    View All

    RXO Schedules First-Quarter 2026 Earnings and Investor Conference Call for May 7, 2026

    RXO (NYSE:RXO) will issue its first-quarter financial results before the opening of the New York Stock Exchange on Thursday, May 7, 2026. The company's results will be made available on www.rxo.com. The company will also hold a conference call at 8 a.m. EDT. Conference Call Access Information Live webcast online at: http://investors.rxo.com Call toll-free from U.S./Canada: +1 800-715-9871 International callers: +1 646-307-1963 Conference ID: 8661113 A replay of the conference call will be available through May 14, 2026, by calling toll-free (from U.S./Canada) +1 800-770-2030; international callers dial +1 609-800-9909. Use the passcode 8661113#. Additionally, the call will be archived

    4/2/26 8:30:00 AM ET
    $RXO
    Transportation Services
    Consumer Discretionary

    Pharming Group reports fourth quarter and full year 2025 financial results, delivering strong revenue growth and profitability with positive cash flow

    Full year 2025 total revenues increased by 27% to US$376.1 million, driven by continued growth of RUCONEST® and rising demand for Joenja® (leniolisib) Fourth quarter 2025 total revenues increased by 15% to US$106.5 million, compared to the fourth quarter 2024RUCONEST® full year revenue increased by 26% to US$317.9 million and fourth quarter revenue increased by 9% to US$86.7 millionJoenja® revenue increased by 29% to US$58.2 million and fourth quarter revenue increased by 53% to US$19.8 millionAchieved US$25.8 million operating profit in 2025, compared to a loss in 2024Achieved US$54.7 million net cash flow from operations in 2025, compared to negative cash flow in the prior year2026 total r

    3/12/26 2:00:00 AM ET
    $PHAR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Clover Health Reports Fourth Quarter & Full Year 2025 Results; Provides Full Year 2026 Guidance

    Business Highlights: Generated full year 2025 Adjusted EBITDA profitability while growing membership by 38% and Insurance revenue by 41% year-over-yearAchieved industry-leading 2026 AEP growth of 53% year-over-year with strong returning member retentionExpect improving cohort economics powered by Clover Assistant to drive our first-ever full year of GAAP Net Income profitability in 2026 Financial Results: Full year 2025 Medicare Advantage membership of 113,803, up 38% year-over-yearFull year 2025 Total revenues of $1.9 billion, up 40% year-over-yearFull year 2025 GAAP Net loss of $86 million, Adjusted EBITDA of $22 million, and Adjusted Net Income of $20 million Full Year 2026 Gu

    2/26/26 4:05:00 PM ET
    $CLOV
    Medical Specialities
    Health Care

    $ALNY
    $ALT
    $ARGX
    $CLOV
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    Financial Insight: Purchase at Clover Health Investments Corp. on Jun 20

    The recent insider purchase at Clover Health Investments Corp. by Director Garipalli Vivek on June 20, 2024, has caught the attention of investors. Director Garipalli Vivek bought $1,000,426 worth of shares, acquiring 877,567 units at $1.14 per share, as reported in SEC Form 4. This insider purchase stands out among recent insider transactions at Clover Health. Looking at the previous transactions, there have been instances of insiders covering exercise/tax liability by selling shares, resulting in a decrease in their direct ownership percentages. For example, Reynoso Jamie L., Priest Brady Patrick, Toy Andrew, Sharp Aric R, Soares Karen, Chief Technology Officer Wai Conrad, and CEO Reynoso

    6/20/24 6:36:05 PM ET
    $CLOV
    Medical Specialities
    Health Care